greeksoup/ stock research
Stock research / United States / GEHC · X-Ray Apparatus & Tubes & Related Irradiation Apparatus · Nasdaq

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare sells medical technology, pharmaceutical diagnostics and artificial intelligence, cloud and software products, earning from medical devices, consumables, service and software. It serves hospitals, health systems and researchers, public, private, academic and government, in over 160 countries, with approximately 9,700 sales professionals and 8,900 field service engineers and approximately 54,000 colleagues in total. It is a Delaware corporation with headquarters in Chicago, and General Electric, which now operates as GE Aerospace, completed the spin-off of the company on 3 January 2023. Results in the fourth quarter have historically been higher than in other quarters because of customer spending patterns. The business runs in four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics.

GE HealthCare Technologies Inc.

GE HealthCare sells medical technology, pharmaceutical diagnostics and artificial intelligence, cloud and software products, earning from medical devices, consumables, service and software. It serves hospitals, health systems and researchers, public, private, academic and government, in over 160 countries, with approximately 9,700 sales professionals and 8,900 field service engineers and approximately 54,000 colleagues in total. It is a Delaware corporation with headquarters in Chicago, and General Electric, which now operates as GE Aerospace, completed the spin-off of the company on 3 January 2023. Results in the fourth quarter have historically been higher than in other quarters because of customer spending patterns. The business runs in four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics.

Imaging

The segment holds five product lines with their service: molecular imaging, computed tomography, magnetic resonance, women's health and X-ray, supporting oncology, cardiology, neurology, nuclear medicine, orthopaedics, paediatrics and surgery. Molecular imaging shows functional processes at cellular and subcellular level, with a range from cyclotrons and chemistry synthesis through positron emission tomography, PET with computed tomography, single-photon emission computed tomography, PET with magnetic resonance and nuclear medicine. Computed tomography renders three-dimensional images of bone, soft tissue and air cavities with a rotating X-ray tube, used to find tumours, blocked blood vessels, abnormal heart conditions, complex fractures and internal injuries. Magnetic resonance produces detailed images of almost every internal structure without invasion and suits detection, diagnosis and treatment monitoring for stroke, cancer, trauma, aneurysm, multiple sclerosis and congenital disorders. Women's health products use X-ray to screen for breast cancer and bone and metabolic disease, with biopsy positioning systems and dual energy absorptiometry scanners, while the X-ray line covers fixed room radiography, mobile units for bedside imaging and fluoroscopy for moving images.

Advanced Visualization Solutions

The segment is organised by clinical speciality and covers two areas the company terms specialised ultrasound and procedural guidance. The filing states that specialised ultrasound splits into comprehensive care ultrasound and women's health ultrasound, and procedural guidance into cardiovascular and interventional products and surgical innovations. The filing states that comprehensive care ultrasound covers screening, diagnosis, monitoring and treatment across the whole body, including liver, thyroid, kidney, breast and vascular work, with point-of-care and handheld devices and tools for measurement quantification, workflow automation and scan guidance.

Patient Care Solutions

The segment covers monitoring and life support. Patient monitoring runs from spot-check to continuous, with multi-parameter monitors, central stations, wearable, mobile and transport monitors, cardiac telemetry and alarm distribution tools, and a meaningful part of it recurs through proprietary parameters and consumables. Diagnostic cardiology supplies resting and stress electrocardiogram devices and management software with interpretation algorithms, capturing and storing traces from hospital and home settings. Maternal infant care supplies neonatal incubators, infant warmers, resuscitation devices, phototherapy equipment, fetal monitors and heart rate surveillance software for labour, delivery and neonatal intensive care, and the anaesthesia line supplies ventilation technology.

Pharmaceutical Diagnostics

The segment supplies contrast and radiopharmaceutical imaging agents to radiology and nuclear medicine, complementing the group's own scanners and working with other vendors' systems. Contrast media are given during scans to raise the visibility of tissues or structures, which matters for small areas such as cancer lesions and for planning angioplasties, biopsies or radiation therapy; the line spans computed tomography, angiography and X-ray, magnetic resonance and ultrasound, with injection devices supplied through third-party manufacturers. Radiopharmaceuticals are molecular tracers labelled with radioisotopes, injected before a scan, that gather at the site of interest and emit energy a scanner detects, supporting diagnosis and therapy selection in neurology, cardiology and oncology and used by drug companies to select trial populations. The filing notes that this is a strictly regulated industry where shortages or delays can disrupt workflows and cancel exams.

Research, selling and supply

Research and development employs approximately 11,100 engineers and scientists worldwide, in hardware, systems and software engineering and clinical research, with work sponsored through collaborations with academic institutions and medical centres. Selling runs through a multi-channel model of the sales force plus a network of over 5,000 indirect third-party partners, with equipment representatives working alongside service sales on maintenance agreements, upgrades and software subscriptions. Manufacturing, assembly and pharmaceutical production sit in 44 facilities across 17 countries, managed globally but serving specific regions, with buffer capacity and diversified sourcing behind the supply chain. The company states that its patents and other intellectual property are vital in aggregate, but that no single asset or group of assets is of material importance to any segment or to the business as a whole.

From GE HealthCare's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in GE HealthCare Technologies became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 28 October 2026
Revenue
$5.5 billion
+7.2% on the year · +4.1% on the quarter
Q4 FY2024Q3 FY2026
Net income
$615 million
+37.9% on the year · +9.6% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.36
+38.8% on the year · +9.7% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 4 February 2026
Revenue
$20.6 billion
+4.8% on the year
FY2021FY2025
Net income
$2.1 billion
+4.6% on the year
FY2021FY2025
Diluted EPS
$4.55
+4.8% on the year
FY2021FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsGE HealthCare Technologies (GEHC) reported revenue of $20.6 billion for fiscal 2025, the year ended 31 December 2025, up 4.8% on the year before. Net income was $2.1 billion and diluted earnings per share $4.55. Revenue was $19.7 billion in fiscal 2024, $19.6 billion in fiscal 2023, $18.3 billion in fiscal 2022 and $17.6 billion in fiscal 2021. Net income in the same years was $2.0 billion, $1.6 billion, $1.9 billion and $2.2 billion. Over the twelve months to 30 September 2026, GE HealthCare Technologies reported revenue of $21.6 billion and net income of $2.2 billion. GE HealthCare Technologies declared $0.14 a share in dividends over the last four quarters and had 452 million shares outstanding at the latest filed count. At 30 September 2026 it carried $10.0 billion of debt and $2.8 billion of cash. At the close of 6 November 2026 the market cap of GE HealthCare Technologies was $37.2 billion, 17.4 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE18.5%
ROCE13.4%
Operating margin13.3%
Net margin10.0%
FCF marginn/a
Interest covern/a
Debt to equity0.86x
Cash conversionn/a
Share count, last 12 months-0.7%
Sales CAGR, 3 years4.0%
Profit CAGR, 3 years2.8%
EPS, TTM$4.74

At the close of 6 November 2026

Price$82.38
Market cap$37.2 billion
Stock P/E17.4x
Price to book3.2x
EV / EBITDA12.7x
Dividend yield0.2%
Market cap / sales1.7x
52-week high$88.16
52-week low$59.49
Price, 1 year11.1%
Price CAGR, 3 years5.2%
Price CAGR, 5 yearsn/a

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as GE HealthCare Technologies Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
GEHCgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue4,3434,4844,5764,9384,7074,8174,8225,2064,6504,8394,8635,3204,7775,0075,1435,6985,1315,2955,513
Gross profit1,6781,7961,7731,9321,8911,9401,9352,1561,9022,0022,0262,2752,0121,9851,9902,2611,9772,1802,224
Gross margin39%40%39%39%40%40%40%41%41%41%42%43%42%40%39%40%39%41%40%
R&D238257260271270298322315324327316344344302292322345323320
SG&A9319089088841,0621,0729961,1521,0381,0671,0341,1301,0401,0291,0451,1111,1171,1181,100
Operating income509631605777559570617689540608676801629654653827515739805
Operating margin12%14%13%16%12%12%13%13%12%13%14%15%13%13%13%15%10%14%15%
Pre-tax income533639622718546570636609512578658833692613643820505693752
Tax rate25%24%21%21%30%24%39%32%24%25%26%12%15%18%28%27%19%17%17%
Net income389485487555372418375403374428470721564486446588389561615
Net margin9%11%11%11%8%9%8%8%8%9%10%14%12%10%9%10%8%11%11%
Diluted EPS$0.86$1.07$1.07$1.22$0.41$0.91$0.82$0.88$0.81$0.93$1.02$1.57$1.23$1.06$0.98$1.29$0.85$1.24$1.36
Operating cash flow468-19.0622n/a468-67.0650n/a419-119n/an/a25094.0593n/a290168907
Capital expenditure10059.074.077.014370.080.094.014564.090.010215286.0110134178100114
Free cash flow368-78.0548n/a325-137570n/a274-183n/an/a98.08.0483n/a11268.0793
Buybacksn/an/an/an/an/an/an/an/an/an/a0.0n/a0.01001000.01002000.0
Dividends paid0.00.00.0n/a0.014.014.013.014.014.013.014.016.016.016.016.016.016.016.0
Shares outstanding455m455m455mn/a455m455m455m455m456m457m457m457m458m457m456m456m455m452m452m
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2021FY2022FY2023FY2024FY2025TTM
Revenue17,58518,34119,55219,67220,62521,637
Gross profit7,1747,1797,9228,2058,2488,642
Gross margin40.8%39.1%40.5%41.7%40.0%39.9%
Research and development8161,0261,2051,3111,2601,310
Selling, general and administrative3,5633,6314,2824,2694,2254,446
Operating income2,7952,5222,4352,6252,7632,886
Operating margin15.9%13.8%12.5%13.3%13.4%13.3%
Pre-tax income2,8752,5122,3612,5812,7682,770
Income tax600563743531614560
Effective tax rate20.9%22.4%31.5%20.6%22.2%20.2%
Net income2,2471,9161,5681,9932,0842,153
Net margin12.8%10.4%8.0%10.1%10.1%10.0%
Diluted EPS$4.95$4.22$3.03$4.34$4.55$4.74
Filing10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Revenue by segment FY2021 to FY2025

FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Imaging9,4338,3958,9448,8559,24544.9%
AVSn/a5,0125,0945,1315,35426.0%
PCS2,9152,9163,1423,1253,08615.0%
PDx2,0181,9582,3062,5082,90014.1%
Ultrasound3,172n/an/an/an/an/a
ImagingAVS FY2022 to FY2025PCSPDxUltrasound FY2021
17.5FY202118.3FY202219.5FY202319.6FY202420.6FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by product or service FY2021 to FY2025

FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Product11,16512,04413,12713,07513,66166.2%
Service6,4206,2976,4256,5976,96433.8%
ProductService
17.6FY202118.3FY202219.6FY202319.7FY202420.6FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by region FY2021 to FY2025

FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
All other countries8,0158,1978,7648,9199,42745.7%
United States7,0607,8198,2288,6179,16844.4%
China2,5102,3252,5602,1352,0319.8%
All other countriesUnited StatesChina
17.6FY202118.3FY202219.6FY202319.7FY202420.6FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow1,6072,1132,1011,9511,987n/a
Capital expenditure248310387401482526
Free cash flow1,3591,8031,7141,5501,505n/a
Free cash flow margin7.7%9.8%8.8%7.9%7.3%n/a
Cash from investing-1,761-398-558-914-1,047-2,995
Cash from financing-263-822-478-573617-548
Depreciation and amortisation625633610580578621
Share-based compensation76.067.0114125130152
Buybacksn/an/a0.00.0200300
Dividends paid0.00.041.055.064.064.0
Dividend per sharen/an/a$0.12$0.12$0.14n/a
Diluted shares, weighted454m454m458m459m458m453m
Shares outstanding at period endn/a100455mn/an/a452m
Filing10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity16,6769,3577,1338,44610,37911,614
Non-controlling interestn/a5.012.018.011.017.0
Redeemable equity220230165188209234
Short-term borrowingsn/a15.01,0061,5025083.0
Debtn/a8,2499,4428,95110,0039,973
Operating lease liabilitiesn/a243273270284255
Finance lease liabilitiesn/a39.038.040.042.052.0
Other liabilitiesn/a9,40114,38513,67415,47016,223
Total liabilities and equityn/a27,53932,45433,08936,90638,371
Owned
Fixed assetsn/a2,0012,144n/an/an/a
Goodwill12,89212,81312,93613,13613,48915,140
Intangible assetsn/a1,5201,2531,0781,1301,812
Investmentsn/a322357373351383
Cash and equivalents5611,4402,4942,8744,4922,826
Inventoryn/a2,1551,9601,9392,2342,628
Other assetsn/a7,28811,31013,68915,21015,582
Total assetsn/a27,53932,45433,08936,90638,371
Filing10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compoundedn/an/a4.0%6.9%
Profit growth, compoundedn/an/a2.8%-2.9%
Return on equity, averagen/a19.9%21.9%20.1%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was GE HealthCare Technologies' revenue in fiscal 2025?

GE HealthCare Technologies (GEHC) reported revenue of $20.6 billion for fiscal 2025, the year ended 31 December 2025, up 4.8% on the year before.

How much did GE HealthCare Technologies earn in fiscal 2025?

Net income was $2.1 billion for fiscal 2025, and diluted earnings per share $4.55.

What is GE HealthCare Technologies' P/E ratio?

At the close of 6 November 2026, GE HealthCare Technologies traded at 17.4 times its earnings over the twelve months to 30 September 2026.

What is GE HealthCare Technologies' market cap?

The market cap of GE HealthCare Technologies was $37.2 billion at the close of 6 November 2026.

Does GE HealthCare Technologies pay a dividend?

Yes. GE HealthCare Technologies declared $0.14 a share in dividends over the four quarters to 30 September 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
2 companies share its SEC industry code (X-Ray Apparatus & Tubes & Related Irradiation Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on GEHC

Dividends$0.145 a share over the four quarters to 30 September 2026, a 0.18% yield
Filings22 in twelve months: 14 current reports (8-K), about 6 officer or director change; 5 results of operations; 3 regulation FD disclosure; 3 other events; 2 material agreement
Planned insider sales2 Form 144 notices in twelve months, $7.1 million; latest 4 November 2026
Options tapeput/call 0.5 by open interest at the 6 November 2026 close; the straddle prices a 3.6% move to 13 November 2026
13F holders1,236 funds reported a position for the quarter to 30 June 2026; largest Dodge & Cox
Insider trading0 sales and 8 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest19.4 million shares short, 5.13 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202628 October 2026EDGAR
10-Q30 June 202629 July 2026EDGAR
10-Q31 March 202629 April 2026EDGAR
10-K31 December 20254 February 2026EDGAR
10-Q30 September 202529 October 2025EDGAR
10-Q30 June 202530 July 2025EDGAR
10-Q31 March 202530 April 2025EDGAR
10-K31 December 202413 February 2025EDGAR
10-Q30 September 202430 October 2024EDGAR
10-Q30 June 202431 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.